Results 21 to 30 of about 2,318,494 (246)

Immune Checkpoint Inhibitors and Neurotoxicity

open access: yesCurrent Neuropharmacology, 2021
: Immune checkpoint inhibitors (ICIs) have recently been used as a promising treatment for cancer, while their toxicity and immune-related side effects can be seen in any organ, including the nervous system. In contrast to other immune-related adverse events (irAEs), neurological irAEs (nAEs) are rare, with ...
Zhao, Zhiyi   +4 more
openaire   +3 more sources

Checkpoint kinase 1 inhibitor + low‐dose hydroxyurea efficiently kills BRAF inhibitor‐ and immune checkpoint inhibitor‐resistant melanomas

open access: yes, 2023
Treatment of melanomas with targeted and immunotherapies has proven effective, but resistance to both treatments is a common outcome leaving a high proportion of patients without effective alternative treatment options.
Helen Rizos   +15 more
core   +1 more source

Immune Checkpoint Inhibitors in NSCLC [PDF]

open access: yesCurrent Treatment Options in Oncology, 2014
Lung cancer is the leading cause of cancer-related mortality worldwide. Cytotoxic chemotherapy and tyrosine kinase inhibitors provide palliation and prolong survival, however, the median survival for patients with metastatic disease remains poor and more effective therapies are needed.
Douglas B, Johnson   +2 more
openaire   +2 more sources

Immune Checkpoint Inhibitor-Related Stress Cardiomyopathy [PDF]

open access: yes, 2023
20.500.12530/87913A 76-year-old man with stage IV urothelial carcinoma who was receiving atezolizumab presented with dyspnea, elevated cardiac biomarkers, new negative T waves, and left ventricular apical akinesia.
Cristina Contreras   +15 more
core   +1 more source

Immune Checkpoint Inhibitor Toxicities [PDF]

open access: yesMayo Clinic Proceedings, 2019
Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been
Julian A. Marin-Acevedo   +2 more
openaire   +2 more sources

Successful treatment of immune checkpoint inhibitor-related periaortitis [PDF]

open access: yes
We report a 64-year-old patient with melanoma receiving ipilimumab and nivolumab therapy who presented with a periaortic soft tissue mass around the abdominal aorta on restaging fluorodeoxyglucose positron emission tomography/computed tomography imaging.
Özdemir, Berna C   +7 more
core   +3 more sources

Supplementary Tables – Developing an immune signature for triple‑negative breast cancer to predict prognosis and immune checkpoint inhibitor

open access: yes, 2022
Supplementary Table S1. Developing an immune signature for triple‑negative breast cancer to predict prognosis and immune checkpoint inhibitor R packages in the study Supplementary Table S2.
Yongfu Yu (477682)   +8 more
core   +1 more source

Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy

open access: yes, 2022
Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor ...
Lars Ny (6788321)   +8 more
core   +1 more source

Cost‐effectiveness and financial risks associated with immune checkpoint inhibitor therapy [PDF]

open access: yes, 2020
The reimbursement of immune checkpoint inhibitor is challenging. Funding these technologies involves the careful balance between awarding innovation and ensuring affordability as increases in drug spending compete directly with other health care and ...
Kim, H   +8 more
core   +1 more source

Immune checkpoint inhibitor myocarditis: a call for standardized histopathologic criteria

open access: yes, 2021
Histopathologic criteria for the diagnosis of myocarditis at endomyocardial biopsy: from the Dallas criteria to those recently proposed for immune checkpoint inhibitor (ICI) myocarditis.
Basso C.   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy